N/A N=37 Randomized Single-blind Treatment

Compassion Meditation for PTSD

Posttraumatic Stress Disorder

Bottom Line

View on ClinicalTrials.gov: NCT02372396 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Sep 2018

Primary outcome: Primary: Clinician Administered PTSD Scale -5 (CAPS-5) PTSD Severity — 35.8; 37.9; 20.4; 35.3 units on a scale

Study Design & Population

Study type: Interventional
Phase: N/A
Interventions: Compassion Meditation (CM) (Behavioral); Relaxation (Behavioral)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: Veterans Medical Research Foundation
Primary completion: Dec 2017

Outcome Measures

Outcome	Result	p-value
PRIMARY Clinician Administered PTSD Scale -5 (CAPS-5) PTSD Severity	35.8; 37.9; 20.4; 35.3	—

Summary

The goal of this project is to refine an existing compassion meditation protocol for individuals with posttraumatic stress disorder (PTSD), to examine the safety and feasibility of this approach and to collect data to make initial estimates of efficacy.

Eligibility Criteria

Inclusion Criteria

Veteran of at least 18 years of age
PTSD as defined by the Diagnostic and Statistical Manual Version 5 (DSM-5)
Capacity to consent
Willing to commit to 8 consecutive weekly sessions lasting 2 hours in duration and to complete assessment materials.

Exclusion Criteria

Serious suicidality or homicidality that has required urgent or emergent evaluation or treatment within the past three months
A known, untreated substance use disorder (inclusion is possible if there is evidence that the individual has been afforded and is complying with treatment for the substance problem)
Serious Axis I mental disorders, such as psychotic disorders or bipolar type I, or serious dissociative symptoms
Cognitive impairment that would interfere with consent or treatment
Circumstances that lead to recurrent traumatization (e.g., engaged in a violent relationship)
Concurrent enrollment in any other treatment specifically targeting PTSD symptoms or social functioning (e.g., couples therapy)

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02372396). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.